EGFR and non-small cell lung carcinoma: Genetic aberrations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) such as L858R mutation and E746‐A750 deletion have been observed in approximately 30% patients with NSCLC and have been identified as key drivers of NSCLC progression 5, 6.